Floatz logo

PREFEST COMPONENT NORGESTIMATE

Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception

University of PennsylvaniaSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

82 Active assets in the Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception cohort.

Asset / SponsorPhaseRating
Tezacaftor
Vertex Pharmaceuticals Incorporated
Phase 4A
Lumacaftor
Hospices Civils de Lyon
Phase 4BBB
Liprotamase
Anthera Pharmaceuticals
Phase 4BBB
Ivacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB
ELEXACAFTOR
Meyer Children's Hospital IRCCS
Phase 4BBB

View all 50 →

Same molecule, other indications

PREFEST COMPONENT NORGESTIMATE is also rated in:

Ovary CystDormant
B
Indicative ·
57 / 100
View asset →
migraine disorderDormant
CC
Indicative ·
47 / 100
View asset →
Depressive Disorder, MajorDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →